STUDY OF ACID REFLUX ASTHMA (SARA)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究旨在确定酸反流(GERD)是否会导致哮喘，以及质子泵抑制剂(PPI)的治疗是否会减少哮喘的恶化。这将作为一项多中心、随机、双掩蔽、平行组临床试验进行，并采用安慰剂对照。在将在全国范围内招募的400名患者中，有22名预计将在这里进行研究。主要的结果衡量标准是治疗期间哮喘加重的比率。积极的终点将包括与安慰剂治疗相比，哮喘恶化的比率更低，哮喘症状更少，生活质量更好，肺功能更好，医疗保健使用更少，呼吸道反应性更好。次要结果包括与峰值流量相关的可测量的肺功能。PPI为埃索美拉唑(奈克索)。这对有症状的哮喘患者可能有很大的好处，他们可以从简单的药物干预(质子泵抑制剂)中受益。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to determine whether acid reflux (GERD) contributes to asthma and whether treatment with a proton-pump inhibitor (PPI) will reduce asthma exacerbations. This will be conducted as a multicenter, randomized, double-masked, parallel-group clinical trial, with a placebo control. Of 400 patients to be recruited nationally, 22 are expected to be studied here. The primary outcome measure is asthma exacerbation rate during treatment. Positive endpoints would include lower rate of asthma exacerbations, fewer asthma symptoms, better quality of life, better lung function, less health care use, and improved airway reactivity compared to those treated with a placebo. Secondary outcomes include measurable lung functions related to peak flow. The PPI is esomeprazole (Nexium). This is potentially of great benefit to symptomatic asthmatics who would benefit from a simple medical intervention (proton pump inhibitor).